tpst-1495
·Code: TPST-1495
tpst-1495: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Tempest Therapeutics, Inc. (TPST) | Phase 1 |
Clinical Trials (1)
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Frequently asked questions
Who is developing tpst-1495?
tpst-1495 is being developed by Tempest Therapeutics, Inc..
How many clinical trials involve tpst-1495?
BioSniper tracks 1 clinical trial involving tpst-1495.
Get deeper analysis on tpst-1495
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis